ZBH Relative Valuation
ZBH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZBH is overvalued; if below, it's undervalued.
Historical Valuation
Zimmer Biomet Holdings Inc (ZBH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 11.79 is considered Undervalued compared with the five-year average of 16.73. The fair price of Zimmer Biomet Holdings Inc (ZBH) is between 135.47 to 171.59 according to relative valuation methord. Compared to the current price of 91.28 USD , Zimmer Biomet Holdings Inc is Undervalued By 32.62%.
Relative Value
Fair Zone
135.47-171.59
Current Price：91.28
32.62%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.51
P/B
Median3y
1.93
Median5y
2.13
6.77
FCF Yield
Median3y
3.99
Median5y
3.71
Competitors Valuation Multiple
The average P/S ratio for ZBH's competitors is 4.14, providing a benchmark for relative valuation. Zimmer Biomet Holdings Inc Corp (ZBH) exhibits a P/S ratio of 2.20, which is -46.75% above the industry average. Given its robust revenue growth of 1.05%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Zimmer Biomet Holdings Inc (ZBH) currently overvalued or undervalued?
What is Zimmer Biomet Holdings Inc (ZBH) fair value?
How does ZBH's valuation metrics compare to the industry average?
What is the current P/B ratio for Zimmer Biomet Holdings Inc (ZBH) as of Jun 16 2025?
What is the current FCF Yield for Zimmer Biomet Holdings Inc (ZBH) as of Jun 16 2025?
What is the current Forward P/E ratio for Zimmer Biomet Holdings Inc (ZBH) as of Jun 16 2025?